Vivos Inc (RDGL)

[SC8]

The product has no shelf life. Y90 decays too fast to ship same formulation from USA to India that one intends to market in USA. But that's what RDGL is doing: testing a different formulation with higher initial Y90 concentration shipped to India. Hence the already announced confirmation they need operations in India. Until then, nothing can come out of India for FDA to consider.

Since a rabbit demonstration would be so much less costly, Occam says the second set of 2023 rabbits we never heard about was an attempt at such a statistically valid demonstration that failed. The should have been end of story for RDGL, unless it's a scam.